This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 452| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2231 | TP73-AS1 | LncRNA | Human | Upregulated in HCC (with more than 2 fold change) | Diagnostic and Prognostic | HCC v/s Normal; associated with worse clinicopathological features, poorer prognosis and shorter survival | p < 0.001 | Tissue | 28403886 |
| 2232 | CCAT2 | LncRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Normal | p < 0.05 | Tissue | 27347113 |
| 2233 | UCA1 | LncRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Normal | p < 0.05 | Tissue | 28271214 |
| 2234 | CCAT2 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; associated with poor survival in HCC patients | p < 0.01 | Tissue | 28280353 |
| 2235 | SNHG20 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; associated with survival of patients | p < 0.001 | Tissue | 27053960 |
| 2236 | MALAT1 | LncRNA | Human, Mice and cell lines | Upregulated in HCC with Fold change=3.233 | Diagnostic | HCC v/s Normal | p < 0.05 | Tissue | 27993818 |
| 2237 | ANRIL | LncRNA | Human | Upregulated in HCC with Fold change >1.0 | Diagnostic | HCC v/s Normal | p < 0.01 | Tissue | 25966845 |
| 2238 | CCAT1 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; correlated with tumor size, microvascular invasion and poor prognosis | p < 0.001 | Tissue | 25884472 |
| 2239 | lncCAMTA1 | LncRNA | Human | Upregulated in HCC and lncCAMTA1 is increased in HCC and indicates poor outcome. | Prognostic | HCC v/s Normal; associated with poor recurrence free survival and overall survival of patients | p < 0.01 | Tissue | 27669232 |
| 2240 | lncRNA-hPVT1 | LncRNA | Human | Upregulated in HCC and higher hPVT1 expression levels in HCC tissues significantly correlated with markedly reduced recurrence-free survival | Diagnostic and Prognostic | HCC v/s Normal; associated with recurrence and survival in patients | p < 0.001 | Tissue | 25043274 |
| 2246 | HLA-C | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 67 fold change) | Diagnostic | HCC and CHC v/s normal | p < 0.01 | Tissue | 11401510 |
| 2247 | B2M | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 67 fold change) | Diagnostic | HCC and CHC v/s normal | p < 0.01 | Tissue | 11401510 |
| 2248 | BR1 | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 19 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2249 | GPC3 | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 15 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2250 | UBD | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 12 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2251 | CXCL10 | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 13 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2252 | CYP3A4 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 42 and 50 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2253 | CYP4A11 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 17 and 30 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2254 | SLC22A1 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 8 and 17 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
| 2255 | Enoyl-CoA hydratase | Protein | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15221772 |
| 2256 | Tropomyosin-beta-chain | Protein | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 15221772 |
| 2257 | Ketohexokinase | Protein | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 15221772 |
| 2258 | Liver type aldolase | Protein | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15221772 |
| 2259 | Arginase 1 | Protein | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 15221772 |
| 2260 | CDK4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2261 | Bax | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2262 | NOTCH4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2263 | ISGF3G | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2264 | TNF | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2265 | VISA | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2266 | AURKB-Sv2 variant | RNAs | Human | Upregulated in metastatic HCC than primary HCC and Absent in normal | Prognostic | Metastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period | p < 0.01 | Cell line and Tissue | 19134008 |
| 2267 | SPP1 | RNAs and Protein | Human | Upregulated in PT than PN (with 3 fold change) | Diagnostic | Metastatic HCC v/s Primary HCC | p < 0.01 | Tissue | 12640447 |
| 2268 | LIMK1, CENPE, FZD2, ENO2, ITGA9, COPA, KIAA0660, GTF2H1, VPS41, RGS20, MATK, STOML1, BASP1, EPB42, ALDH3B2, MEL, CAT56, RAB3A, PSCD3, PLD2, ADCYAP1R1, ALDH3B1, RHD, CSF3R, KIAA0063, KIAA0296, LRP6, ENO3, CTRB1, YES1, IncytePD:1404153, GYS1, MDFI, GABRE, IncytePD:2685601, CD3Z, DTYMK, SPTBN2, IncyteP | RNAs | Human | Upregulated in PT than PN (with 3 fold change) | Diagnostic | Metastatic HCC v/s Primary HCC | p < 0.01 | Tissue | 12640447 |
| 2269 | Phosphoserine aminotransferase | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 3.8) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2270 | IFP53/Tryptophanyl-Trna synthetase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.27) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2271 | Peroxiredoxin 3 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.82) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2272 | GRP94 (Tumor rejection antigen 1) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2273 | Annexin A1 (Phospholipase A2 inhibitory protein) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.52) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2274 | Superoxide dismutase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.44) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2275 | Annexin A2 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.42) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2276 | Annexin A4 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.6) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2277 | L-lactate dehydrogenase B chain | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.61) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2278 | Cyclophilin B (Peptidyl-prolyl cis-trans isomerase B) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.53) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2279 | ORP150 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2280 | Vinculin | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.82) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2281 | Flavin reductase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.52) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2282 | Stathmin | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.56) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2283 | Protein kinase C inhibitor protein-1 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 2.7) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2284 | Heterogeneous nuclear ribonucleoprotein A2/B1 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.55) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2285 | 26S proteasome non-ATPase regulatory subunit 8 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |